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Disturbances in mineral and bone metabolism are prevalent in
chronic kidney disease (CKD) and are an important cause of
morbidity, decreased quality of life, and extraskeletal
calcification that have been associated with increased
cardiovascular mortality. These disturbances have traditionally
been termed renal osteodystrophy and classified based on bone
biopsy. Kidney Disease: Improving Global Outcomes (KDIGO)
sponsored a Controversies Conference on Renal Osteodystrophy
to (1) develop a clear, clinically relevant, and internationally
acceptable definition and classification system, (2) develop a
consensus for bone biopsy evaluation and classification, and (3)
evaluate laboratory and imaging markers for the clinical
assessment of patients with CKD. It is recommended that (1) the
term renal osteodystrophy be used exclusively to define
alterations in bone morphology associated with CKD, which can
be further assessed by histomorphometry, and the results
reported based on a unified classification system that includes
parameters of turnover, mineralization, and volume, and (2) the
term CKD-Mineral and Bone Disorder (CKD-MBD) be used to
describe a broader clinical syndrome that develops as a systemic
disorder of mineral and bone metabolism due to CKD, which is
manifested by abnormalities in bone and mineral metabolism
and/or extra-skeletal calcification. The international adoption of
these recommendations will greatly enhance communication,
facilitate clinical decision-making, and promote the evolution of
evidence-based clinical practice guidelines worldwide.
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Chronic kidney disease (CKD) is a worldwide public health
problem, with increasing prevalence and adverse outcomes,
including progressive loss of kidney function, cardiovascular
disease, and premature death.1 Disturbances in mineral
metabolism and bone disease are common complications of
CKD and an important cause of morbidity and decreased
quality of life. Importantly, there is increasing evidence
suggesting that these disorders in mineral and bone
metabolism are associated with increased risk for cardiovas-
cular calcification, morbidity, and mortality.2 The underlying
mechanisms for this linkage are not completely understood,
but are probably related to an effect on vascular calcification
(VC) leading to changes in cardiovascular structure and
function.3,4 Evaluation of extraskeletal calcification therefore
becomes an essential component in the work up and
classification of the mineral and bone disorders in patients
with CKD.
Renal osteodystrophy is the term that has been used
traditionally to describe the abnormalities in bone morphol-
ogy that develop in CKD.5–8 In clinical practice, bone biopsy
is used infrequently because it is an invasive and often
expensive procedure and the samples obtained require
specialized processing that is not widely available. The
most common forms of renal osteodystrophy are attri-
butable largely to variations in the plasma levels of
parathyroid hormone (PTH). As such, circulating PTH levels
have been used as a surrogate indicator of bone turnover,
which are used together with measurements of serum
calcium, phosphorus, and alkaline phosphatase levels to
evaluate, diagnose, and guide the treatment of renal
osteodystrophy. However, the specificity of PTH as an
indicator of bone turnover has been questioned.9,10 Several
other circulating biochemical markers of bone formation and
resorption have been investigated as clinical indicators of
bone turnover,11,12 but their clinical applicability remains to
be established.
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In addition to bone histology and serum biomarkers,
imaging has been an important component of evaluating
bone disease in the past, and remains the main tool in
assessing extraskeletal calcification in CKD patients.13 On-
going developments in non-invasive imaging techniques
almost certainly will lead to their improved and more
widespread use in clinical diagnosis and decision-making in
the near future.14 In principle, the definition, evaluation, and
classification of the mineral abnormalities and bone disease
in CKD should include all three clinical components: serum
biomarkers, non-invasive imaging, and bone abnormalities.
Unfortunately, to date, there is no clear definition of renal
osteodystrophy that incorporates all these components of
disorders in mineral and bone metabolism encountered in
CKD.
At the 2003 National Kidney Foundation Controversies
Conference on Mineral Metabolism and Bone Disease in
CKD, the following definition for renal osteodystrophy was
proposed: A constellation of bone disorders present or
exacerbated by chronic kidney disease that lead to bone fragility
and fractures, abnormal mineral metabolism, and extraskeletal
manifestations.15 This definition, which incorporates the
relevant elements of mineral and bone abnormalities and
soft tissue calcification, has failed to gain worldwide
acceptance. The historical absence of a generally accepted
definition and diagnosis of renal osteodystrophy indicates the
need for an international consensus, which the Board of
Directors of Kidney Disease: Improving Global Outcomes
(KDIGO) selected as a priority issue to address.
KDIGO was established in 2003 as an independently
incorporated non-profit foundation governed by an interna-
tional board of directors with the stated mission to ‘improve
the care and outcomes of kidney disease patients worldwide
through promoting coordination, collaboration and integra-
tion of initiatives to develop and implement clinical practice
guidelines’. One of the initiatives adopted by the KDIGO
Board of Directors is a series of international Controversies
Conferences to examine what is known, what can be done
with what is known, and what needs to be known on
controversial topics of clinical relevance. The first KDIGO
Controversies Conference on ‘Definition and Classification of
Chronic Kidney Disease’ was held in 2004.16
The second KDIGO Controversies Conference on ‘Defini-
tion, Evaluation, and Classification of Renal Osteodystrophy’
was held on September 15–17, 2005 in Madrid, Spain. The
specific objectives for this conference were to
1. develop a clinically relevant, easily applicable definition
and classification system for the constellation of
disorders heretofore known as renal osteodystrophy;
2. examine current histologic categories of renal osteody-
strophy and develop consensus on a unified evaluation
and classification of bone histology; and
3. evaluate and assess the clinical utility of serum markers
and imaging procedures that can allow the non-invasive
diagnosis and classification of mineral and bone
disorders specifically associated with CKD with reason-
able accuracy.
The adoption of a clear definition and improved classifica-
tion scheme based on readily available clinical parameters
would greatly enhance the direction of future research and
the development and implementation of evidence-based
clinical practice guidelines for the management of mineral
and bone abnormalities in CKD.
CONFERENCE PROCEEDINGS
KDIGO co-chairs (G Eknoyan and N Lameire) identified the
conference co-chairs (T Dru¨eke and S Moe) and worked
together to develop the agenda and participants list. Meeting
participants were chosen based on their demonstrated
expertise in mineral and bone metabolism and interest in
global issues in guideline development and implementation.
The conference was attended by more than 70 physicians,
representing six continents and 21 countries (see Appendix
A1). Prior to the conference, each of the participants was
invited to submit an abstract of their work and concerns to
facilitate the meeting discussions. Those abstracts and the
conference agenda can be found at www.kdigo.org.
The meeting started with a plenary session during which a
series of presentations were made, designed to provide both a
historical perspective and an overview of recent develop-
ments in the areas of bone biopsy and histomorphometry,
serum markers of bone metabolism, and assessment of bone
health with imaging techniques. The plenary session was
followed by breakout sessions of three separate work groups
to address the following topics: bone biopsy and histomor-
phometry, biomarkers, and imaging techniques. Each of the
work groups was asked to make recommendations on a
name, definition, and classification system for the disorder.
They were also challenged to critically examine the diagnostic
parameters specific to their topic area and make recommen-
dations on their utility and validity in the evaluation of the
disease, and to make recommendations to guide clinical
research studies aimed at evaluating the adequacy of their
proposals. Owing to the complexity of the meeting objectives
for the bone biopsy work group, members of this group were
invited to begin their deliberations a day earlier than those of
the other two work groups.
On the final day, work group leaders presented a summary
of their group’s deliberations and recommendations to the
entire conference assembly. After discussion and refinement
of the recommendations, the conference participants prior-
itized and voted on the recommendations. This paper
contains the specific recommendations made at the meeting.
It has been reviewed by the participants and approved as a
position statement by the KDIGO Board of Directors.
FRAMING THE ISSUES
There was general agreement among the conference attendees
on the following issues:
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1. The traditional definition of renal osteodystrophy does
not completely depict the underlying bone pathology or
reflect the full spectrum of symptoms associated with
mineral and bone disorders in CKD.
2. Bone biopsy remains a powerful and informa-
tive diagnostic tool for the determination of bone
abnormalities. However, owing to its limited use, a
biopsy-based definition and classification system does
not provide an adequate means in clinical practice to
clearly identify and classify CKD patients with mineral
and bone disorders.
3. Although the mechanisms involved are still poorly
understood, there is a clear association in CKD patients
between mineral and bone abnormalities and the
incidence and severity of VC and cardiovascular
morbidity and mortality. The presence of abnormal
values of circulating markers such as plasma phosphorus,
as well as the presence and extent of VC, is associated
with increased cardiovascular and all-cause morbidity
and mortality in CKD stage 5 patients on hemodialysis.17
Minimizing abnormalities in biochemical markers, such
as hyperphosphatemia and hypercalcemia, and slowing
or halting the progression of extraskeletal calcification is
considered a critical component of the management of
CKD patients for the prevention of bone disease and
other related morbidities and mortality.18–20
RECOMMENDATIONS FOR DEFINITION, EVALUATION, AND
CLASSIFICATION OF RENAL OSTEODYSTROPHY
The principal conclusion from the conference was that the
current descriptive nomenclature for this pathophysiologic
process should be reconsidered. It is recommended that the
term renal osteodystrophy be used exclusively to define the
bone pathology associated with CKD. The many clinical,
biochemical, and imaging abnormalities that have heretofore
been identified as correlates of renal osteodystrophy should
be defined more broadly as a clinical entity or syndrome to be
called chronic kidney disease-mineral and bone disorder (CKD-
MBD). Conference participants examined these two issues
separately and made recommendations for the definition,
evaluation, and classification of each.
Renal osteodystrophy
Definition of renal osteodystrophy. The meeting partici-
pants agreed on a definition of renal osteodystrophy that is
specific to bone pathology found in patients with CKD
(Table 1). Renal osteodystrophy is one component of the
mineral and bone disorders that occur as a complication of
CKD.
Evaluation of renal osteodystrophy. The evaluation and
definitive diagnosis of renal osteodystrophy requires a bone
biopsy. Histomorphometry is not essential for clinical
diagnosis, but should be performed in research studies.
There was unanimous agreement that histomorphometric
results are to be reported using standard nomenclature as
recommended by the American Society for Bone and Mineral
Research,21 and that investigators would supply primary
measurements used to report any derived parameters.
Classification of renal osteodystrophy. In order to clarify
the interpretation of bone biopsy results in the evaluation of
renal osteodystrophy, it was agreed to use three key histologic
descriptors – bone turnover, mineralization, and volume
(TMV system) – with any combination of each of the
descriptors possible in a given specimen (Table 2). The TMV
classification scheme provides a clinically relevant description
of the underlying bone pathology as assessed by histomor-
phometry, which in turn helps define the pathophysiology,
and thereby guide therapy.
Chronic kidney disease-mineral and bone disorder
Definition of CKD-MBD. The meeting participants agreed
on a definition of CKD-MBD (Table 3) that incorporates
elements of abnormal mineral metabolism, altered bone
structure and composition, and extraskeletal calcification
with the following caveats:
K Bone disease and VC are discreet entities that are
not exclusive to the CKD population.
K Bone disease and VC are multifactorial processes,
and disturbances in mineral metabolism due to
CKD may not be their primary underlying etiology.
K The evidence for a link between mineral distur-
bances and VC in CKD is not yet fully established.
Evaluation of CKD-MBD. The initial evaluation of CKD-
MBD should include PTH, calcium (either ionized or total
corrected for albumin), phosphorus, alkaline phosphatases
(total or bone-specific), bicarbonate, and imaging for soft
tissue calcification.
K If there are inconsistencies in the biochemical
markers (e.g. high PTH but low alkaline phospha-
tases), unexplained bone pain, or unexplained
fractures, a bone biopsy would be indicated.
Table 1 | Definition of renal osteodystrophy
Renal osteodystrophy is an alteration of bone morphology in patients
with CKD
It is one measure of the skeletal component of the systemic disorder of
CKD-MBD that is quantifiable by histomorphometry of bone biopsy.
CKD, chronic kidney disease; CKD-MBD, chronic kidney disease-mineral and bone
disorder.
Table 2 | TMV classification system for renal osteodystrophy
Turnover Mineralization Volume
Low Low
Normal
Normal Normal
Abnormal
High High
TMV, bone turnover, mineralization, and volume.
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K Additional tests to assess linear growth rate are
needed in children with CKD.
A proposed framework for classification of CKD-MBD. Di-
sease classification systems can be simple or complex and
may be based on severity, prognosis, outcomes, symptoms, or
treatment modalities. General considerations in the adoption
of a classification system include (1) availability of support-
ing data, (2) ease of clinical use, and (3) appropriateness in
guiding clinical therapy.
An ideal classification system for CKD-MBD would allow
categorization of patients based on readily available clinical
diagnostic tools and would help guide treatment. The lack of
adequate data and the nonlinearity of the disease process do
not allow for the development of a classification based on
severity or treatment at this time. The proposed framework
for classifying CKD-MBD (Table 4) divides patients into four
types based on the presence or absence of abnormalities in
the three primary components used in the definition of the
disorder: laboratory abnormalities (L), bone disease (B), and
calcification of extraskeletal tissue (C). This framework is
meant to be descriptive rather than predictive, as an initial
attempt to improve communication and stimulate research.
It is a working model that may have to be modified and
improved in the future depending on further analysis of new
data that become available. This simple framework lends
itself to subsequent critical evaluation and refinement based
on analysis of patient databases or the prospective evaluation
of CKD patients.
Coexistence of CKD-MBD with other causes of bone and
vascular disease. The use of CKD-MBD should be as specific
as possible and limited to disturbances caused by significantly
reduced kidney function. In general, adult patients with a
glomerular filtration rate of 460 ml/min/1.73 m2 should be
excluded, as this is the level of glomerular filtration rate
below which abnormalities in calcium, phosphorus, PTH,
and vitamin D metabolism are detectable. In pediatric
patients, the level of glomerular filtration rate at which
CKD-MBD abnormalities are detectable is higher (glomer-
ular filtration rateo89 ml/min/1.73 m2). On the other hand,
increased bone fragility observed with aging (senile or post-
menopausal osteoporosis) and atherosclerotic disease with
calcification that develops independent of CKD can be
present in patients with CKD who have normal or only
slightly reduced kidney function, and can coexist with CKD-
MBD after its onset. This is an important consideration, as
CKD may alter the diagnosis, treatment, and prognosis of
osteoporosis and atherosclerosis. Bone, in particular, is likely
to be more severely affected by CKD than might be expected
from normal aging, either because of the extremes of
turnover or remodeling that occur in CKD in adults and
children, or because of abnormalities of modeling that occur
in growing children. This in turn might have a major impact
on bone strength, perhaps even more so than that of altered
bone mass or volume. Because of this, the term osteoporosis
should not be used in describing altered bone fragility in
CKD patients.22 By the same token, several studies have
demonstrated that for any age group the atherosclerotic
lesions are more calcified in CKD patients than in the general
population.23 The presence of increased calcification in these
cases may affect the response to common therapies such as
angioplasty. Thus, although CKD-MBD should refer to
conditions that are caused by CKD, the precise contribution
of CKD-related changes to disease states commonly found in
the general population will require increased understanding
of the underlying pathophysiology, more sensitive diagnostic
tools, and a different therapeutic approach.
WORK GROUP-SPECIFIC RECOMMENDATIONS
Assessment of bone by histomorphometry (co-chairs
W Goodman and S Ott)
1. Indications for bone biopsy: Bone biopsy is not recom-
mended as part of the routine evaluation for CKD-MBD, but
remains a valuable diagnostic tool in the clinical evaluation
and differential diagnosis of bone disease in selected patients
with CKD. The clinical indications for bone biopsy include,
but are not limited to the following:
K inconsistencies among biochemical parameters that
preclude a definitive interpretation,
K unexplained skeletal fracture or bone pain,
K severe progressive VC,
K unexplained hypercalcemia,
K suspicion of overload or toxicity from aluminum,
and possibly other metals,
K before parathyroidectomy if there has been sig-
nificant exposure to aluminum in the past or if the
results of biochemical determinations are not
consistent with advanced secondary or tertiary
hyperparathyroidism, and
Table 4 | A framework for classification of CKD-MBD
Typea
Laboratory
abnormalities
Bone
disease
Calcification of
vascular or other
soft tissue
L +  
LB + + 
LC +  +
LBC + + +
aL, laboratory abnormalities (of calcium, phosphate, PTH, alkaline phosphatases, or
vitamin D metabolism); B, bone disease (abnormalities in bone turnover,
mineralization, volume, linear growth, or strength); C, calcification of vascular or
other soft tissue.
CKD-MBD, chronic kidney disease-mineral and bone disorder; PTH, parathyroid
hormone.
Table 3 | Definition of CKD-MBD
A systemic disorder of mineral and bone metabolism due to CKD
manifested by either one or a combination of the following:
Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism
Abnormalities in bone turnover, mineralization, volume, linear growth,
or strength
Vascular or other soft tissue calcification
CKD, chronic kidney disease; CKD-MBD, chronic kidney disease-mineral and bone
disorder; PTH, parathyroid hormone.
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K to be considered before beginning treatment with
bisphosphonates.
2. Histologic classification based upon TMV (turnover/
mineralization/volume): A standardized nomenclature for
reporting the results of bone histomorphometry, both for
clinical and for research purposes, has been provided by the
American Society for Bone and Mineral Research
(ASBMR).21 It is recommended that the same nomenclature
be utilized for the assessment of renal osteodystrophy to
promote a more widespread and consistent understanding of
bone histomorphometry and the information that it
provides. Such an approach would also facilitate valid
comparisons among results from various research reports.
If calculated parameters are used, it is expected that the
primary measurements used to derive them are made
available, using appendices or internet databases as necessary.
The components used to classify renal osteodystrophy
include turnover, mineralization, and bone volume using the
TMV classification system (Table 2). This new classification is
consistent with the current commonly used one,24 but
provides more information on parameters other than turn-
over (Figure 1).
1. Turnover reflects the rate of skeletal remodeling, which is
normally the coupled process of bone resorption and
bone formation. It is assessed with histomorphometry by
dynamic measurements of osteoblast function using the
technique of double-tetracycline labeling. Bone forma-
tion rates and activation frequency represent acceptable
parameters for assessing bone turnover. When bone
formation rate is reported, the referent (bone surface,
area, volume or tissue volume) should be specified. If
expressed as a categorical variable (low, normal, or high),
the cutoff values should be included. Bone turnover is
affected mainly by hormones, cytokines, mechanical
stimuli, and growth factors that influence the recruit-
ment, differentiation, and activity of osteoclasts and
osteoblasts.
It is important to clarify that although bone formation
rate is frequently similar to bone resorption rate, which
cannot be measured directly, this is not always true.
Imbalance in these processes can affect bone volume. For
example, excess resorption over formation will lead to
negative bone balance and decreased bone volume.
2. Mineralization reflects how well bone collagen becomes
calcified during the formation phase of skeletal remodel-
ing. It is assessed with histomorphometry by static
measurements of osteoid volume and osteoid thickness
and by dynamic, tetracycline-based measurements of
mineralization lag time and osteoid maturation time.
Causes of impaired mineralization include inadequate
vitamin D nutrition, mineral deficiency, acidosis, or
bone aluminum toxicity.
3. Volume indicates the amount of bone per unit volume of
tissue. It is assessed with histomorphometry by static
measurements of bone volume in cancellous bone.
Sometimes, measurements of cortical bone volume and
thickness may provide additional useful information.
Determinants of bone volume in the general population
and CKD patients include age, gender, race, genetic
factors, nutrition, endocrine disorders, mechanical
stimuli, toxicities, neurological function, vascular supply,
growth factors, and cytokines.
3. Reporting of results: It is recommended that publications
that report histomorphometric measurements should include
the following details in the methods section: biopsy
technique, specimen size, tetracycline protocol, assessment
of sample adequacy (e.g. exclusions due to crush artifacts),
tissue area that was measured, magnification, minimal
osteoid width measured, and normative data source when
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Figure 1 | TMV classification system for bone histomorphometry.
The figure is a graphical example of how the TMV system provides
more information than the present, commonly used classification
scheme. Each axis represents one of the descriptors in the TMV
classification: turnover (from low to high), mineralization (from
normal to abnormal), and bone volume (from low to high). Individual
patient parameters could be plotted on the graph, or means and
ranges of grouped data could be shown. For example, many patients
with renal osteodystrophy cluster in areas shown by the bars. The red
bar (OM, osteomalacia) is currently described as low-turnover bone
with abnormal mineralization. The bone volume may be low to
medium, depending on the severity and duration of the process and
other factors that affect bone. The green bar (AD, adynamic bone
disease) is currently described as low-turnover bone with normal
mineralization, and the bone volume in this example is at the lower
end of the spectrum, but other patients with normal mineralization
and low turnover will have normal bone volume. The yellow bar (mild
HPT, mild hyperparathyroid-related bone disease) and purple bar (OF,
osteitis fibrosa or advanced hyperparathyroid-related bone disease)
are currently used distinct categories, but in actuality represent a
range of abnormalities along a continuum of medium to high
turnover, and any bone volume depending on the duration of
the disease process. Finally, the blue bar (MUO, mixed uremic
osteodystrophy) is variably defined internationally. In the present
graph, it is depicted as high-turnover, normal bone volume, with
abnormal mineralization. In summary, the TMV classification
system more precisely describes the range of pathologic
abnormalities that can occur in patients with CKD.
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appropriate. Each reporting laboratory should perform
assessment studies of their methodology precision.
4. Quality assurance: There is a clear need to establish a
cooperative international initiative to facilitate the develop-
ment of a global quality assurance program and a data
collection mechanism for bone histomorphometry results in
CKD. Objectives include the following:
K Develop a quality control and assurance protocol
with ongoing inter-laboratory exchange of bone
biopsy material to determine the variability of
histomorphometric results among laboratories and
to promote standardization for the reporting of
results.
K Develop a mechanism to collect all currently
available normative data for bone biopsies, includ-
ing an international effort to prospectively obtain
bone biopsy samples from healthy volunteers. This
should include evaluation of age, gender, and race
variations in different geographic regions.
Research questions and considerations related to bone
histomorphometry.
1. What changes in bone histomorphometry parameters
occur as CKD progresses from stage 2 to 5?
2. What is the relationship of bone histomorphometric
abnormalities to vascular and other soft tissue calcifica-
tions?
3. What is the relationship of bone histomorphometric
abnormalities to the diminished linear growth in
children?
4. What are the functional properties of bone in the
maintenance of systemic calcium homeostasis?
5. What is the relationship between bone histomorpho-
metric abnormalities and clinical outcomes?
6. How can bone biopsy be utilized best in clinical practice?
7. How do non-invasive techniques relate to histomorpho-
metric findings?
8. How can more clinicians be trained to do bone biopsies
and how can the number of centers doing bone
histomorphometry be increased?
Assessment of biomarkers (co-chairs K Martin and K Olgaard)
This work group evaluated the clinical utility of biomarkers
used in the assessment of mineral and bone abnormalities in
CKD shown in Table 5.
1. Bone activity markers: Although several serum or urine
markers of bone activity have been investigated, there
was general agreement that serum PTH levels remain the
best clinical indicator of bone turnover at this time.
Nearly all the currently available information on the
correlation of PTH with bone histomorphometry and
outcomes has been obtained with ‘intact’ PTH assays.
Whereas the current published studies supporting a
clinical advantage in measuring 1-84 PTH over the
traditional ‘intact’ PTH assays are controversial, it is
anticipated that commercial assays that measure only the
1-84 PTH peptide will gain increasing acceptance owing
to their superior reproducibility across sites. Additional
investigation is needed to determine the effect of 7-84
PTH and other large fragments of PTH on bone and the
possible clinical value of the 7-84 PTH to 1-84 PTH
ratio.
2. Serum Calcium: Measurement of ionized calcium is the
preferred method for evaluating serum calcium. How-
ever, the sample processing and cost involved with
routine ionized calcium measurement may preclude its
clinical use. If total serum calcium concentration is used,
it should be ‘corrected’ for albumin if its serum level is
low, although there is currently a lack of standardization
of the formulas used to determine ‘corrected calcium’
(National Kidney Foundation,25 Guideline 6).
3. Alkaline phosphatases: Serum total alkaline phosphatases,
in conjunction with PTH, can be helpful in predicting
bone turnover.26 Bone-specific alkaline phosphatase has
marginal advantages, but it probably does not warrant
the additional cost of measurement.
4. Serum biomarkers: The biomarkers, osteocalcin, osteo-
protegerin, TRAP-5b, pyridinoline, deoxypyridinoline,
procollagen type 1 amino-terminal extension peptides,
and C-terminal crosslinks, have not been adequately
studied in patients with CKD stage 3–5. A problem with
several of these biomarkers is their kidney-dependent
elimination that affects their measured levels depending
on the degree of kidney dysfunction.
Research questions and considerations related to biomarkers.
1. Do the current formulas used to ‘correct’ serum total
calcium based on serum albumin level provide a more
accurate representation of calcium status than uncor-
rected serum total calcium?
2. What is the correlation of mineral and bone biomarker
values to (1) morbidity and mortality, (2) bone fracture
risk and occurrence, (3) bone histomorphometry data,
(4) soft tissue calcifications, and (5) growth rate in
children?
Table 5 | Serum biomarkers examined by the biomarkers
work group
PTH (‘Intact’) Osteocalcin
1-84 PTH Osteoprotegerin
1-84 PTH/7-84 PTH ratio TRAP-5b
Phosphorus Pyridinoline and deoxypyridinoline
Calcium
Calciumphosphorus product
Procollagen type 1 amino-terminal
extension peptides
Bicarbonate CTX
Alkaline phosphatases 25(OH)-vitamin D
Total FGF23
Bone-specific Fetuin-A
CTX, C-terminal crosslinks; FGF 23, fibroblast growth factor 23; PTH, parathyroid
hormone; TRAP-5b, tartrate-resistant acid phosphatase. isoform 5b.
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3. What is the precise role of C-terminal PTH fragments
and the 7-84 PTH to 1-84 PTH ratio in the assessment of
CKD-MBD and how can PTH assays be standardized
internationally?
4. What is the preferred inter-dialytic interval for assessing
serum phosphorus (e.g. after 2 or 3 days off dialysis)?
5. What is the role of Fetuin-A and FGF2327,28 levels in the
evaluation of CKD-MBD?
6. What is the role of other markers of bone metabolism in
the evaluation of CKD-MBD?
7. What is the role of measuring 25(OH)-vitamin D levels
in the assessment of CKD-MBD, and which assay is
preferable in CKD?
8. How often must biomarkers be measured in stable
clinical condition vs evolving high or low bone turnover
disease to assess CKD-MBD?
Assessment of imaging techniques (co-chairs J Cunningham
and S Sprague)
The radiologic imaging techniques used in the evaluation of
the skeletal system and extraskeletal calcification that were
considered are shown in Table 6.
1. Bone mineral density measurement:
K The value of bone density measurement (BMD) in
the evaluation of CKD-MBD is not well established.
Findings on the correlation of BMD values to
fracture risk in the CKD population are incon-
sistent. However, several studies have shown that
when BMD is measured at the distal radius site, it is
predictive of fracture risk29 and correlates well with
PTH levels30 in hemodialysis patients. Distal radius
is therefore the preferred site of measurement in
CKD patients. This is consistent with the recom-
mendations of International Society of Clinical
Densitometry in their 2005 Official Position State-
ment (http://www.iscd.org/Visitors/positions).
K There is concern that hip or spine BMD results,
without full consideration of the underlying bone
pathology, may be misleading and result in the
inappropriate administration of anti-osteoporotic
therapy to CKD patients.
K Serial BMD measurements are valuable in the
evaluation of bone disease in kidney transplant
recipients in adults (National Kidney Foundation,25
Guideline 16), but not in children (National Kidney
Foundation,31 Guideline 2). Their role in CKD-MBD
in adults and children remains to be determined.
K BMD measurement by quantitative computed
tomography is valuable in differentiating cortical
from trabecular bone. This is particularly advanta-
geous in CKD-MBD, where hyperparathyroidism
can lead to sclerotic thickening of trabecular bone
with increased BMD but stimulates resorption in
cortical bone with significant reductions in BMD. In
contrast, low-turnover bone disorders frequently
result in reductions in trabecular BMD.32
2. Bone strength and quality: The contribution of bone
mass to bone strength is of uncertain value in patients with
CKD who actually exhibit a wide spectrum of bone quality.
Unfortunately, technologies that assess bone quality and
strength are currently not available for clinical use. Plain X-ray
films provide minimal information in the evaluation of CKD-
MBD in the majority of CKD patients. Exceptions are
advanced forms of bone disease such as severe osteitis fibrosa
(subperiosteal resorption) or severe osteomalacia (Looser
zones). However, radiographs remain an important part of
the ongoing evaluation of CKD-MBD in children with CKD.31
3. Assessment of VC: Lateral abdominal radiography is a
simple, low-cost screening tool for the detection of VC in
adults.33 The presence of visible aortic calcification on lateral
abdominal radiographs indicates a positive VC finding,
which can be submitted to semiquantitative evaluation.
Although computed tomography scans may be more precise
and/or sensitive for the quantitative assessment of VC than
radiography, their use is not justified as a screening tool
owing to limited availability in some areas and substantial
additional cost.
Research questions and considerations related to imaging.
1. Does BMD measurement – hip or radial – predict hip
fracture risk and occurrence in CKD patients?
2. Is there a relationship between changes in BMD and VC?
3. Is there an association between BMD values with
biochemical marker values?
4. Can BMD be used in conjunction with biochemical
marker values to define bone CKD-MBD or guide therapy?
5. What impact does delayed onset of puberty, post-
menopausal status, corticosteroids, or senile osteoporosis
have on CKD-MBD? Can BMD help in assessing this?
6. Can assessment of bone microarchitecture by radiologic
techniques aid in the evaluation of CKD-MBD?
Table 6 | Evaluation techniques examined by imaging work
group
Bone mineral density – DXA (measures area
per cm2): Bone architecture:
Lumbar spine Micro-MRI/CT
Hip Radioisotope imaging
Radius Extraskeletal calcification:
Bone mineral density – qCT (measures
volume per cm3)
EBCT/MSCT
Bone structure:
Abdominal radiograph
Hand radiograph
CT scan
Hip radiograph
Vascular stiffness:
Skull radiograph
Pulse wave velocity
Clavicle radiograph
Ultrasound
Pulse pressure
DXA, dual-energy X-ray absorptiometry; EBCT, electron beam computed tomogra-
phy; micro-MRI/CT, micro-magentic resonance imaging/computed tomography;
MSCT, multislice computed tomography; qCT, quantitative computed tomography.
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7. What is the validity (sensitivity and specificity) of plain
abdominal radiography in the assessment of VC?
8. What is the relationship between the radiologic VC
assessments and measurements of vascular stiffness such
as pulse wave velocity and pul se pressure?
9. Is the presence and extent of coronary artery calcification
predictive of mortality in CKD?
CONCLUSION
Mineral and bone disorders are complex abnormalities that
cause morbidity and decreased quality of life in patients with
CKD. In order to enhance communication and facilitate
research, a more precise terminology of these abnormalities is
needed. It is recommended that (1) the term CKD-MBD
should be used to describe the syndrome of biochemical,
bone, and extra-skeletal calcification abnormalities that occur
in patients with CKD; and (2) the term renal osteodystrophy
should be used exclusively to define alterations in bone
morphology associated with CKD. The latter can be further
assessed by histomorphometry with results reported based on
a classification system that includes parameters of turnover,
mineralization, and volume. It is expected that the interna-
tional adoption of the proposed uniform terminology,
definition, and classification to describe these two disorders
due to CKD will greatly enhance communication, facilitate
clinical decision-making, and promote the evolution of
evidence-based clinical practice guidelines worldwide. Addi-
tional evidence-based evaluation is required to determine the
(1) correlation of outcomes with the various biochemical
parameters, (2) sensitivity and specificity of the available
measures of both bone strength and VC, and (3) assessment
of the effects of available treatment modalities on the
outcomes in CKD-MBD.
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